Compare BIO-TECHNE Corp (TECH) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Financial Select Sector SPDR Fund — how do they compare? BIO-TECHNE Corp trades at $71.63 (market cap $11.16B), while Financial Select Sector SPDR Fund trades at $56.07. The key difference: BIO-TECHNE Corp pays a 0.45% dividend while Financial Select Sector SPDR Fund pays none. Which is the better fit depends on your goals.
| TECH | XLF | |
|---|---|---|
Market Cap | $11.16B | — |
Sector | Health | — |
52-Week High | $72.12 | $56.75 |
52-Week Low | $43.31 | $47.80 |
Enterprise Value | $11.24B | — |
Dividend Yield | 0.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
XLF trades at $56.04, down 0.39% on the day, with technical indicators showing a bullish moving average trend but overbought RSI signals. The ETF benefits from strong bank earnings and dividend increases following Fed stress tests. Recent news highlights regional bank strength and AI-driven capital markets activity as key growth drivers.
Outlook remains positive due to robust financial sector performance and potential Fed rate hikes, though geopolitical risks and overbought conditions pose near-term headwinds. The ETF offers exposure to banking sector resilience with a low expense ratio of 0.08%.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
